Protein structures in virtual screening: A case study with CDK2

Journal of Medicinal Chemistry

Volumn 49, Issue 1, 2006, Pages 92-104

  Thomas, Mark P ^a   McInnes, Campbell ^a   Fischer, Peter M ^a,b  

^a CYCLACEL LTD   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 2 INHIBITOR; LIGAND;

ACCURACY; ARTICLE; BINDING SITE; COMPUTER PROGRAM; CRYSTAL STRUCTURE; ENZYME INHIBITION; HYDROGEN BOND; PROTEIN STRUCTURE; SCREENING; STRUCTURE ANALYSIS; VIRTUAL REALITY;

BINDING SITES; CYCLIN-DEPENDENT KINASE 2; HYDROGEN BONDING; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; SOFTWARE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 30444442998     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050554i     Document Type: Article

References (56)

1. Kuntz, I. D.; Blaney, J. M.; Oatley, S. J.; Langridge, R.; Ferrin, T. E. A geometric approach to macromolecule-ligaiid interactions. J. Mol. Biol. 1982, 161, 269-288.
2. Goodsell, D. S.; Morris, G. M.; Olson, A. J. Automated docking of flexible ligands: Applications of AutoDock. J. Mol. Recognit. 1996, 9, 1-5.
3. Rarey, M.; Wefing, S.; Lengauer, T. Placement of medium-sized molecular fragments into active sites of proteins. J. Comput. Aided Mol. Des. 1996, 10, 41-54.
4. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
5. Venkatachalam, C. M.; Jiang, X.; Oldfield, T.; Waldman, M. LigandFit: A novel method for the shape-directed rapid docking of ligands to protein active sites. J. Mol. Graphics Modell. 2003, 21, 289-307.
6. Stahl, M.; Rarey, M. Detailed analysis of scoring functions for virtual screening. J. Med. Chem. 2001, 44, 1035-1042.
7. Wang, R.; Lu, Y.; Wang, S. Comparative evaluation of 11 scoring functions for molecular docking. J. Med. Chem. 2003, 46, 2287-2303.
8. Ferrara, P.; Gohlke, H.; Price, D. J.; Klebe, G.; Brooks III, C. L. Assessing scoring functions for protein-ligand interactions. J. Med. Chem. 2004, 47, 3032-3047.
9. Kellenberger, E.; Rodrigo, J.; Muller, P.; Rognan, D. Comparative evaluation of eight docking tools for docking and virtual screening accuracy. Proteins: Struct. Funct. Bioinf. 2004, 57, 225-242.
10. Kontoyianni, M.; McClellan, L. M.; Sokol, G. S. Evaluation of docking performance: Comparative data on docking algorithms. J. Med. Chem. 2004, 47, 558-565.
11. Perola, E.; Walters, W. P.; Charifson, P. S. A detailed comparison of current docking and scoring methods on systems of pharmaceutical relevance. Proteins: Struct. Funct. Bioinf. 2004, 56, 235-249.
12. Charifson, P. S.; Corkery, J. J.; Murcko, M. A.; Walters, W. P. Consensus scoring: A method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins. J. Med. Chem. 1999, 42, 5100-5109.
13. Bissantz, C.; Folkers, G.; Rognan, D. Protein-based virtual screening of chemical databases. I. Evaluation of different docking/scoring combinations. J. Med. Chem. 2000, 43, 4759-4767.
14. Terp, G. E.; Johansen, B. N.; Christensen, I. T.; Jørgensen, F. S. A new concept for multidimensional selection of ligand conformations (MultiSelect) and multidimensional scoring (MultiScore) of protein-ligand binding affinities. J. Med. Chem. 2001, 44, 2333-2343.
15. Clark, R. D.; Strizhev, A.; Leonard, J. M.; Blake, J. F.; Matthew, J. B. Consensus scoring for ligand/protein interactions. J. Mol. Graphics Modell. 2002, 20, 281-295.
16. Jacobsson, M.; Lidén, P.; Stjernschantz, E.; Boström, H.; Norinder, U. Improving structure-based virtual screening by multivariate analysis of scoring data. J. Med. Chem. 2003, 46, 5781-5789.
17. Joseph-McCarthy, D. Computational approaches to structure-based ligand design. Pharmacol. Ther. 1999, 84, 179-191.
18. Carlson, H. A.; McCammon, J. A. Accommodating protein flexibility in computational drug design. Mol. Pharmacol. 2000, 57, 213-218.
19. Halperin, I.; Ma, B.; Wolfson, H.; Nussinov, R. Principles of docking: An overview of search algorithms and a guide to scoring functions. Proteins: Struct. Funct. Genet. 2002, 47, 409-443.
20. Shoichet, B. K.; McGovern, S. L.; Wei, B.; Irwin, J. J. Lead discovery using molecular docking. Curr: Opin. Chem. Biol. 2002, 6, 439-446.
21. Brooijmans, N.; Kuntz, I. D. Molecular recognition and docking algorithms. Annu. Rev. Biophys. Biomol. Struct. 2003, 32, 335-373.
22. Alvarez, J. C. High-throughput docking as a source of novel drug leads. Curr. Opin. Chem. Biol. 2004, 8, 365-370.
23. Hou, T.; Xu, X. Recent development and application of virtual screening in drug discovery: An overview. Curr. Pharm. Des. 2004, 10, 1011-1033.
24. Oprea, T. I.; Matter, H. Integrating virtual screening in lead discovery. Curr. Opin. Chem. Biol. 2004, 8, 349-358.
25. Ferrari, A. M.; Wei, B. Q.; Costantino, L.; Shoichet, B. K. Soft docking and multiple receptor conformations in virtual screening. J. Med. Chem. 2004, 47, 5076-5084.
26. Birch, L.; Murray, C. W.; Hartshorn, M. J.; Tickle, I. J.; Verdonk, M. L. Sensitivity of molecular docking to induced fit effects in influenza virus neuraminidase. J. Comput. Aided Mol. Des. 2002, 16, 855-869.
27. Erickson, J. A.; Jalaie, M.; Robertson, D. H.; Lewis, R. A.; Vieth, M. Lessons in molecular recognition: The effects of ligand and protein flexibility on molecular docking accuracy. J. Med. Chem. 2004, 47, 45-55.
28. McGovern, S. L.; Shoichet, B. K. Information decay in molecular docking screens against holo, apo, and modeled conformations of enzymes. J. Med. Chem. 2003, 46, 2895-2907.
29. Wu, S. Y.; McNae, I.; Kontopidis, G.; McClue, S. J.; McInnes, C.; Stewart, K. J.; Wang, S.; Zheleva, D. I.; Marriage, H.; Lane, D. P.; Taylor, P.; Fischer, P. M.; Walkinshaw, M. D. Discovery of a novel family of CDK inhibitors with the program LIDAEUS: Structural basis for ligand-induced disordering of the activation loop. Structure 2003, 11, 399-410.
30. Wang, S., Meades, C., Wood, G.; Osnowski, A., Anderson, S., Yuill, R., Thomas, M., Mezna, M., Jackson, W., Midgley, C., Griffiths, G., Fleming, I., Green, S., McNae, I., Wu, S.-Y., McInnes, C., Zheleva, D., Walkinshaw, M. D., Fischer, P. M. 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: Synthesis, SAR analysis, X-ray crystallography, and biological activity. J. Med. Chem. 2004, 47, 1662-1675.
31. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. Glide: A new approach for rapid, accurate docking and scoring. I. Method and assessment of docking accuracy. J. Med. Chem. 2004, 47, 1739-1749.
32. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235-242.
33. De Azevedo, W. F.; Leclerc, S.; Meijer, L.; Havlicek, L.; Strnad, M.; Kim, S.-H. Inhibition of cyclin-dependent kinases by purine analogues: Crystal structure of human cdk2 complexed with rosco-vitine. Eur. J. Biochem. 1997, 243, 518-526.
34. Kroemer, R. T., Vulpetti, A., McDonald, J. J., Rohrer, D. C., Trosset, J.-Y., Giordanetto, F., Cotesta, S., McMartin, C., Kihlén, M., Stouten, P. F. Assessment of docking poses: Interactions-based accuracy classification (IBAC) versus crystal structure deviations. J. Chem. Inf. Comput. Sci. 2004, 44, 871-881.
35. Lawrie, A. M.; Noble, M. E. M.; Tunnah, P.; Brown, N. R.; Johnson, L. N.; Endicott, J. A. Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2. Nature Struct. Biol. 1997, 4, 796-801.
36. Brown, N. R.; Noble, M. E. M.; Lawrie, A. M.; Morris, M. C.; Tunnah, P.; Divita, G.; Johnson, L. N.; Endicott, J. A. Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity. J. Biol. Chem. 1999, 274, 8746-8756.
37. Shewchuk, L.; Hassell, A.; Wisely, B.; Rocque, W.; Holmes, W.; Veal, J.; Kuyper, L. F. Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase. J. Med. Chem. 2000, 43, 133-138.
38. Meijer, L.; Thunnissen, A.-M. W. H.; White, A. W.; Garnier, M.; Nikolic, M.; Tsai, L.-H.; Walter, J.; Cleverley, K. E.; Salinas, P. C.; Wu, Y.-Z.; Biernat, J.; Mandelkow, E.-M.; Kim, S.-H.; Pettit, G. R. Inhibition of cyclin-dependent kinases. GSK-3/3 and CKI by hymenialdisine. a marine sponge constituent. Chem. Biol. 2000, 7, 51-63.
39. Arris, C. E.; Boyle, F. T.; Calvert, A. H.; Curtin, N. J.; Endicott, J. A.; Garman, E. F.; Gibson, A. E.; Golding, B. T.; Grant, S.; Griffin, R. J.; Jewsbury, P.; Johnson, L. N.; Lawrie, A. M.; Newell, D. R.; Noble, M. E. M.; Sausville, E. A.; Schultz, R.; Yu, W. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J. Med. Chem. 2000, 43, 2797-2804.
40. Jeffrey, P. D.; Russo, A. A.; Polyak, K.; Gibbs, E.; Hurwitz, J.; Massagué, J.; Pavletich, N. P. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 1995, 376, 313-320.
41. Davis, S. T.; Benson, B. G.; Bramson, H. N.; Chapman, D. E.; Dickerson, S. H.; Dold, K. M.; Eberwein, D. J.; Edelstein, M.; Frye, S. V.; Gampe, R. T. Jr.; Griffin, R. J.; Harris, P. A.; Hassell, A. M.; Holmes, W. D.; Hunter, R. N.; Knick, V. B.; Lackey, K.; Lovejoy, B.; Luzzio, M. J.; Murray, D.; Parker, P.; Rocque, W. J.; Shewchuk, L.; Veal, J. M.; Walker, D. H.; Kuyper, L. F. Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors. Science 2001, 291, 134-137.
42. Dreyer, M. K.; Borcherding, D. R.; Dumont, J. A.; Peet, N. P.; Tsay, J. T.; Wright, P. S.; Bitonti, A. J.; Shen, J.; Kim, S.-H. Crystal structure of human cyclin-dependent kinase 2 in complex with the adenine-derived inhibitor H717. J. Med. Chem. 2001, 44, 524-530.
43. 6-substituted guanine derivatives. J. Med. Chem. 2002, 45, 3381-3393.
44. Beattie, J. F.; Breault, G. A.; Ellston, R. P. A.; Green, S.; Jewsbury, P. J.; Midgley, C. J.; Naven, R. T.; Minshull, C. A.; Pauptit, R. A.; Tucker, J. A.; Pease, J. E. Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part I: Identification and optimisation of substituted 4,6-bis anilino pyrimidines. Bioorg. Med. Chem. Lett. 2003, 13, 2955-2960.
45. Davies, T. G.; Bentley, J.; Arris, C. E.; Boyle, F. T.; Curtin, N. J.; Endicott, J. A.; Gibson, A. E.; Golding, B. T.; Griffin, R. J.; Hardcastle, I. R.; Jewsbury, P.; Johnson, L. N.; Mesguiche, V.; Newell, D. R.; Noble, M. E. M.; Tucker, J. A.; Wang, L.; Whitfield, H. J. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nature Struct. Biol. 2002, 9, 745-749.
46. Schulze-Gahmen, U.; De Bondt, H. L.; Kim, S.-H. High-resolution crystal structures of human cyclin-dependent kinase 2 with and without ATP: Bound waters and natural ligand as guides for inhibitor design. J. Med. Chem. 1996, 39, 4540-4546.
47. Schulze-Gahmen, U.; Brandsen, J.; Jones, H. D.; Morgan, D. O.; Meijer, L.; Vesely, J.; Kim, S.-H. Multiple modes of ligand recognition: Crystal structures of cyclin-dependent kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyl-adenine. Proteins: Struct. Func. Genet. 1995, 22, 378-391.
48. Furet, P.; Meyer, T.; Strauss, A.; Raccuglia, S.; Rondeau, J.-M. Structure-based design and protein X-ray analysis of a protein kinase inhibitor. Bioorg. Med. Chem. Lett. 2002, 12, 221-224.
49. Anderson, M.; Beattie, J, F.; Breault, G. A.; Breed, J.; Byth, K. F.; Culshaw, J. D.; Ellston, R. P. A.; Green, S.; Minshull, C. A.; Norman, R. A.; Pauptit, R. A.; Stanway, J.; Thomas, A. P.; Jewsbury, P. J. Imidazo[1,2-α] pyridines: A potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation. Bioorg. Med. Chem. Lett. 2003, 13, 3021-3026.
50. Gray, N. S.; Wodicka, L.; Thunnissen, A.-M. W. H.; Norman, T. C.; Kwon, S.; Espinoza, F. H.; Morgan, D. O.; Barnes, G.; LeClerc, S.; Meijer, L.; Kim, S.-H.; Lockhart, D. J.; Schultz., P. G. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 1998, 281, 533-538.
51. Davies, T. G.; Tunnah, P.; Meijer, L.; Marke, D.; Eisenbrand, G.; Endicott, J. A.; Noble, M. E. M. Inhibitor binding to active and inactive CDK2: The crystal structure of CDK2-cyclin A/indirubin-5-sulphonate. Structure 2001, 9, 389-397.
52. Clare, P. M.; Poorman, R. A.; Kelley, L. C.; Watenpaugh, K. D.; Bannow, C. A.; Leach, K. L. The cyclin-dependent kinases cdk2 and cdk5 act by a random, anticooperative kinetic mechanism. J. Biol. Chem. 2001, 276, 48292-48299.
53. Bramson, H. N.; Corona, J.; Davis, S. T.; Dickerson, S. H.; Edelstein, M.; Frye, S. V.; Gampe, R. T. Jr.; Harris, P. A.; Hassell, A.;, Holmes, W. D.; Hunter, R. N.; Lackey, K. E.; Lovejoy, B.; Luzzio, M. J.; Montana, V.; Rocque, W. J.; Rusnak, D.; Shewchuk, L.; Veal, J. M.; Walker, D. H.; Kuyper, L. F. Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): Design, synthesis, enzymatic activities, and X-ray crystallographic analysis. J. Med. Chem. 2001, 44, 4339-4358.
54. Sayle, K. L.; Bentley, J.; Boyle, F. T.; Calvert, A. H.; Cheng, Y.; Curtin, N. J.; Endicott, J. A.; Golding, B. T.; Hardcastle, I. R.; Jewsbury, P.; Mesguiche, V.; Newell, D. R.; Noble, M. E. M.; Parsons, R. J.; Pratt, D. J.; Wang, L. Z.; Griffin, R. J. Structure-based design of 2-arylamino-4- cyclohexylmethyl-5-nitroso-6-amino-pyrimidine inhibitors of cyclin-dependent kinases 1 and 2. Bioorg. Med. Chem. Lett. 2003, 13, 3079-3082.
55. Liu, J.-J.; Dermatakis, A.; Lukacs, C.; Konzelmann, F.; Chen, Y.; Kammlott, U.; Depinto, W.; Yang, H.; Yin, X.; Chen, Y.; Schutt, A.; Simcox, M. E.; Luk, K.-C. 3,5,6-trisubstituted naphthostyrils as CDK2 inhibitors. Bioorg. Med. Chem. Lett. 2003, 13, 2465-2468.
56. Moshinsky, D. J.; Bellamacina, C. R.; Boisvert, D. C.; Huang, P.; Hui, T.; Jancarik, J.; Kim, S.-H.; Rice, A. G. SU9516: Biochemical analysis of cdk inhibition and crystal structure in complex with cdk2. Biochem. Biophys. Res. Commun. 2003, 310, 1026-1031.